Raghu Kumar
Senior Scientist Ionis Pharmaceuticals, Inc.
Dr. Raghu Penke has over 15 years of experience in pulmonary disease research, this speaker specializes in target identification, in vivo validation, and translational models of lung fibrosis, asthma, and cancer. Dr. Penke brings deep expertise in single-cell and transcriptomic platforms, drug delivery systems, including a patented liposomal platform, and fibroblast-based high-throughput screening. His work spans academic-industrial collaborations and NIH-funded research, with 25+ peer-reviewed publications and extensive mentorship. His focus on lung organoids and mechanistic insight into tissue injury, immune response, and fibrotic progression positions them at the forefront of respiratory therapeutic development.
Seminars
- Inhaled antisense as a novel paradigm for lung therapeutics
- Advancing innovative technology enables the targeting, interrogation, and validation of genes associated with IPF that may be difficult to reach with other approaches
- Exploring MUC5B as a Novel IPF Target: Pros, Cons, and Proof-of-Concept Data
